Logo image of NYXH

NYXOAH SA (NYXH) Stock Price, Quote, News and Overview

NASDAQ:NYXH - Nasdaq - BE0974358906 - Common Stock - Currency: USD

10.347  -0.05 (-0.51%)

NYXH Quote, Performance and Key Statistics

NYXOAH SA

NASDAQ:NYXH (2/21/2025, 8:00:01 PM)

10.347

-0.05 (-0.51%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High20
52 Week Low6.76
Market Cap387.29M
Shares37.43M
Float23.09M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-13 2025-03-13/amc
IPO09-18 2020-09-18


NYXH short term performance overview.The bars show the price performance of NYXH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20

NYXH long term performance overview.The bars show the price performance of NYXH in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50

The current stock price of NYXH is 10.347 USD. In the past month the price decreased by -0.22%. In the past year, price decreased by -39.2%.

NYXOAH SA / NYXH Daily stock chart

NYXH Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 28.89 234.01B
ISRG INTUITIVE SURGICAL INC 80.74 211.07B
BSX BOSTON SCIENTIFIC CORP 41.63 154.00B
SYK STRYKER CORP 31.4 145.92B
MDT MEDTRONIC PLC 16.84 115.33B
BDX BECTON DICKINSON AND CO 16.35 65.30B
EW EDWARDS LIFESCIENCES CORP 27.98 43.23B
GEHC GE HEALTHCARE TECHNOLOGY 20.29 41.62B
IDXX IDEXX LABORATORIES INC 40.25 37.07B
DXCM DEXCOM INC 53.81 34.68B
RMD RESMED INC 26.21 34.03B
PHG KONINKLIJKE PHILIPS NVR- NY 17.5 24.02B

About NYXH

Company Profile

NYXH logo image Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 147 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Company Info

NYXOAH SA

Rue Edouard Belin 12

Mont-Saint-Guibert BRABANT-WALLON BE

CEO: Olivier Taelman

Employees: 147

Company Website: https://www.nyxoah.com/

Phone: 3226121755

NYXOAH SA / NYXH FAQ

What is the stock price of NYXOAH SA today?

The current stock price of NYXH is 10.347 USD. The price decreased by -0.51% in the last trading session.


What is the ticker symbol for NYXOAH SA stock?

The exchange symbol of NYXOAH SA is NYXH and it is listed on the Nasdaq exchange.


On which exchange is NYXH stock listed?

NYXH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NYXOAH SA stock?

14 analysts have analysed NYXH and the average price target is 15.74 USD. This implies a price increase of 52.09% is expected in the next year compared to the current price of 10.347. Check the NYXOAH SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NYXOAH SA worth?

NYXOAH SA (NYXH) has a market capitalization of 387.29M USD. This makes NYXH a Small Cap stock.


How many employees does NYXOAH SA have?

NYXOAH SA (NYXH) currently has 147 employees.


What are the support and resistance levels for NYXOAH SA (NYXH) stock?

NYXOAH SA (NYXH) has a support level at 10.34 and a resistance level at 10.91. Check the full technical report for a detailed analysis of NYXH support and resistance levels.


Is NYXOAH SA (NYXH) expected to grow?

The Revenue of NYXOAH SA (NYXH) is expected to grow by 24.94% in the next year. Check the estimates tab for more information on the NYXH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NYXOAH SA (NYXH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NYXOAH SA (NYXH) stock pay dividends?

NYXH does not pay a dividend.


When does NYXOAH SA (NYXH) report earnings?

NYXOAH SA (NYXH) will report earnings on 2025-03-13, after the market close.


What is the Price/Earnings (PE) ratio of NYXOAH SA (NYXH)?

NYXOAH SA (NYXH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.8).


What is the Short Interest ratio of NYXOAH SA (NYXH) stock?

The outstanding short interest for NYXOAH SA (NYXH) is 0.32% of its float. Check the ownership tab for more information on the NYXH short interest.


NYXH Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to NYXH. When comparing the yearly performance of all stocks, NYXH is a bad performer in the overall market: 70.57% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NYXH Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NYXH. The financial health of NYXH is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NYXH Financial Highlights

Over the last trailing twelve months NYXH reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS decreased by -2.14% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -37.11%
ROE -50.6%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-86.47%
Sales Q2Q%29.71%
EPS 1Y (TTM)-2.14%
Revenue 1Y (TTM)32.65%

NYXH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 81% to NYXH. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -9.57% and a revenue growth 24.94% for NYXH


Ownership
Inst Owners32.66%
Ins Owners20.26%
Short Float %0.32%
Short Ratio1.49
Analysts
Analysts81.43
Price Target15.74 (52.12%)
EPS Next Y-9.57%
Revenue Next Year24.94%